haemophilia B

Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issue

https://pharmaphorum.com/news/sanofi-eyes-2022-filing-for-haemophilia-drug-fitusiran-despite-safety-issue/

FDA lifts hold on uniQure gene therapy after cancer case review

https://pharmaphorum.com/news/fda-lifts-hold-on-uniqure-gene-therapy-after-cancer-case-review/

$2bn deal sees uniQure license haemophilia B gene therapy to CSL Behring

https://pharmaphorum.com/news/2bn-deal-sees-uniqure-license-haemophilia-b-gene-therapy-to-csl-behring/

Pfizer moves haemophilia gene therapy into phase 3

https://pharmaphorum.com/r-d/pfizer-haemophilia-b-gene-therapy/

Spark/Pfizer eye phase 3 trial of haemophilia B gene therapy

https://pharmaphorum.com/news/spark-pfizers-haemophilia-b-drug-dramatically-reduces-bleeds/

After losing out on two big deals, Sanofi to buy Bioverativ for $11.6bn

https://pharmaphorum.com/news/losing-two-big-deals-sanofi-buys-bioverativ-11-6bn/

‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shine

https://pharmaphorum.com/news/cure-hemophilia-within-reach-biomarin-spark-gene-therapies-shine/

Spark and Pfizer’s gene therapy wows in haemophilia B

https://pharmaphorum.com/news/spark-pfizers-gene-therapy-wows-haemophilia-b/

Spark and Pfizer’s haemophilia gene therapy gets European PRIME status

https://pharmaphorum.com/news/spark-pfizers-haemophilia-b-gene-therapy-gets-priority-medicines-access/

Close in 10 seconds

Pharmaphorum.com

Search